Retrospective observational study of the conditions of use, safety and efficacy of MYLOTARG® (Gemtuzumab Ozogamicin, GO) in the treatment of patients with newly diagnosed CD33-positive acute myeloid leukaemia (AML). (MYLobs) First published 07/01/2022 Last updated 18/12/2024 EU PAS number:EUPAS44551 Study Finalised